Stockreport

Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II

KITOV PHARAMCEUTICALS HOLDINGS LTD AMERICAN DEPOS  (KTOV) 
US:NASDAQ Investor Relations: kitovpharma.com
PDF Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or M [Read more]